Hepatitis E virus: Current concepts and future perspectives

Current Infectious Disease Reports

Volumn 16, Issue 4, 2014, Pages

  Dalton, Harry R ^a,b   Pas, Suzan D ^c   Madden, Richie G ^a   Van Der Eijk, Annemiek A ^c  

^a ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic liver disease; Epidemiology; Hepatitis; Hepatitis E; Zoonosis

Indexed keywords

IMMUNOGLOBULIN G;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BLOOD DONOR; CLINICAL FEATURE; DEVELOPED COUNTRY; DIFFERENTIAL DIAGNOSIS; FEVER; HEADACHE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HYPERTRANSAMINASEMIA; JAUNDICE; LABORATORY TEST; LETHARGY; MYALGIA; PRURITUS; REVIEW; SEROLOGY; SEROPREVALENCE; VASCULARIZATION; VIREMIA; VOMITING; WEIGHT REDUCTION;

EID: 84894483871     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0399-8     Document Type: Review

References (107)

1. Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology. 1991;185:120-31.
2. Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci U S A. 1992;89:8259-63.
3. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science. 1990;247:1335-9.
4. Graff J, Torian U, Nguyen H, Emerson SU. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J Virol. 2006;80:5919-26. (Pubitemid 43849169)
5. Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H, et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A. 2009;106:12986-91.
6. .• Li SW, Zhang J, He ZQ, Gu Y, Liu RS, Lin J, et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem. 2005;280:3400-6. This is the first structural and funtional study on hepatitis E virus using crystallography, giving insight on virus-host interactions. (Pubitemid 40223803)
7. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol. 2009;83:12714-24.
8. Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci U S A. 2011;108:10266-71.
9. Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Rev Med Virol. 2012;22:339-49.
10. Meng J, Dai X, Chang JC, Lopareva E, Pillot J, Fields HA, et al. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology. 2001;288:203-11. (Pubitemid 32929900)
11. Korkaya H, Jameel S, Gupta D, Tyagi S, Kumar R, Zafrullah M, et al. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. J Biol Chem. 2001;276:42389-400.
12. Chandra V, Kar-Roy A, Kumari S, Mayor S, Jameel S. The hepatitis E virus ORF3 protein modulates epidermal growth factor receptor trafficking, STAT3 translocation, and the acute-phase response. J Virol. 2008;82:7100-10. (Pubitemid 351977728)
13. Kar-Roy A, Korkaya H, Oberoi R, Lal SK, Jameel S. The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase. J Biol Chem. 2004;279:28345-57. (Pubitemid 38900114)
14. Nagashima S, Takahashi M, Jirintai, Tanaka T, Yamada K, Nishizawa T, et al. A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol. 2011;92:269-78.
15. Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS One. 2010;5:e13560.
16. Gupta E, Pandey P, Pandey S, Sharma MK, Sarin SK. Role of hepatitis E virus antigen in confirming active viral replication in patients with acute viral hepatitis E infection. J Clin Virol 2013.
17. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrouste C, Dubois M, Mansuy JM, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis. 2010;202:835-44.
18. Pas SD, Streefkerk HRA, Pronk M, de Man RA, Beersma MF, Osterhaus ADME, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. Journal of Clinical Virology Accepted.
19. Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, et al. Hepatitis E Virus Infection among Solid Organ Transplant Recipients, the Netherlands. Emerg Infect Dis. 2012;18:869-72.
20. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8:698-709.
21. •• Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379:2477-88. Comprehensive review of hepatitis E from a multinational group of opinion leaders. This is a "must read" for those interested in the field.
22. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82:799-805.
23. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W. Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis. 2013;207:497-500.
24. Herremans M, Bakker J, Duizer E, Vennema H, Koopmans MP. Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity. Clin Vaccine Immunol. 2007;14:562-8.
25. Elkady A, Tanaka Y, Kurbanov F, Hirashima N, Sugiyama M, Khan A, et al. Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection. J Gastroenterol. 2007;42:911-7. (Pubitemid 350142772)
26. Legrand-Abravanel F, Thevenet I, Mansuy JM, Saune K, Vischi F, Peron JM, et al. Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol. 2009;16:772-4.
27. Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis. 2010;51:e24-7.
28. Schnegg A, Burgisser P, Andre C, Kenfak-Foguena A, Canellini G, Moradpour D, et al. An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PLoS One. 2013;8:e62980.
29. Pas SD, Streefkerk HRA, Pronk M, de Man RA, Beersma MF, Osterhaus ADME, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. submitted.
30. Baylis SA, Hanschmann KM, Blumel J, Nubling CM. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol. 2011;49:1234-9.
31. •• Baylis SA, Blumel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, et al. World health organization international standard to harmonize assays for detection of hepatitis e virus RNA. Emerg Infect Dis. 2013;19:729-35. Previous studies have shown very little interlaboratory concordance for HEV quantitative PCR. This paper defines WHO standards to harmonise HEV PCR assays and is a key paper in terms of laboratory diagnosis.
32. Abravanel F, Chapuy-Regaud S, Lhomme S, Dubois M, Peron JM, Alric L, et al. Performance of two commercial assays for detecting hepatitis E virus RNA in acute or chronic infections. J Clin Microbiol. 2013;51:1913-6.
33. Mokhtari C, Marchadier E, Haim-Boukobza S, Jeblaoui A, Tesse S, Savary J, et al. Comparison of real-time RT-PCR assays for hepatitis E virus RNA detection. J Clin Virol. 2013;58:36-40.
34. Aggarwal R. Hepatitis E: clinical presentation in disease-endemic areas and diagnosis. Semin Liver Dis. 2013;33:30-40.
35. Zhai L, Dai X, Meng J. Hepatitis E virus genotyping based on full-length genome and partial genomic regions. Virus Res. 2006;120:57-69. (Pubitemid 43947301)
36. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5-36. (Pubitemid 43133591)
37. Oliveira-Filho EF, Konig M, Thiel HJ. Genetic variability of HEV isolates: inconsistencies of current classification. Vet Microbiol. 2013;165:148-54.
38. Fu H, Wang L, Zhu Y, Geng J, Li L, Wang X, et al. Analysing complete genome sequence of swine hepatitis E virus (HEV), strain CHN-XJ-SW13 isolated from Xinjiang, China: putative host range, and disease severity determinants in HEV. Infect Gen Evol J Mol Epidemiol Evol Genetics Infect Dis. 2011;11:618-23.
39. Batts W, Yun S, Hedrick R, Winton J. A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii). Virus Res. 2011;158:116-23.
40. Backer JA, Berto A, McCreary C, Martelli F, van der Poel WH. Transmission dynamics of hepatitis E virus in pigs: estimation from field data and effect of vaccination. Epidemics. 2012;4:86-92.
41. • Izopet J, Dubois M, Bertagnoli S, Lhomme S, Marchandeau S, Boucher S, et al. Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis. 2012;18:1274-81. HEVis demonstrated in farmed and wild rabbits in France and may have the potential to cause human disease.
42. Purcell RH, Engle RE, Rood MP, Kabrane-Lazizi Y, Nguyen HT, Govindarajan S, et al. Hepatitis E virus in rats, Los Angeles, California, USA. Emerg Infect Dis. 2011;17:2216-22.
43. •• Berto A, Martelli F, Grierson S, Banks M. Hepatitis E virus in pork food chain, United Kingdom, 2009-2010. Emerg Infect Dis. 2012;18:1358-60. A comprehensive study of HEVin pig products in the human food chain from slaughter to retail stores used by the public. HEV is demonstrated in every step of this chain and was found in 10% of pork sausages that were tested.
44. Barnaud E, Rogee S, Garry P, Rose N, Pavio N. Thermal inactivation of infectious hepatitis E virus in experimentally contaminated food. Appl Environ Microbiol. 2012;78:5153-9.
45. •• Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, Ellis V, et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis. 2011;17:2309-12. Using a highly sensitive assay, this paper shows that the HEV IgG seroprevalence in blood donors from the Southwest of France was 52%. This is much higher than previous estimates and suggests that HEV is hyperendemic in this region. These findings are congruent with the extrememy high incidence of hepatitis E that has been found in the Toulouse transplant population.
46. Said B, Ijaz S, Chand MA, Kafatos G, Tedder R, Morgan D. Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products. Epidemiol Infect 2013:1-9.
47. Ishida S, Yoshizumi S, Ikeda T, Miyoshi M, Goto A, Matsubayashi K, et al. Detection and molecular characterization of hepatitis E virus in clinical, environmental and putative animal sources. Arch Virol. 2012;157:2363-8.
48. Madden RG, Hunter JG, Stone AM, Thornton C, Barlow M, Lewis J, et al. Locally acquired hepatitis E. Geographical clustering and environmental factors: a nested case control study. J Hepatol. 2012;56:S64-5.
49. Crossan C, Baker PJ, Craft J, Takeuchi Y, Dalton HR, Scobie L. Hepatitis E virus genotype 3 in shellfish, United Kingdom. Emerg Infect Dis. 2012;18:2085-7.
50. • Slot E, Hogema B, Riezebos-Brilman A, Kok T, Molier M, Zaaijer H. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill 2013; 18. HEV was denonstrated in 1 of 2,671 blood donors in the Netherlands by PCR.
51. Beale MA, Tettmar K, Szypulska R, Tedder RS, Ijaz S. Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors? Vox Sang. 2011;100:340-2.
52. Faramawi MF, Johnson E, Chen S, Pannala PR. The incidence of hepatitis E virus infection in the general population of the USA. Epidemiol Infect. 2011;139:1145-50.
53. Drobeniuc J, Greene-Montfort T, Le NT, Mixson-Hayden TR, Ganova-Raeva L, Dong C, et al. Laboratory-based surveillance for hepatitis E virus infection, United States, 2005-2012. Emerg Infect Dis. 2013;19:218-22. This is the first structural and funtional study on hepatitis E virus using crystallography, giving insight on virus-host interactions.
54. Colson P, Romanet P, Moal V, Borentain P, Purgus R, Benezech A, et al. Autochthonous infections with hepatitis E virus genotype 4, France. Emerg Infect Dis. 2012;18:1361-4.
55. Garbuglia AR, Scognamiglio P, Petrosillo N, Mastroianni CM, Sordillo P, Gentile D, et al. Hepatitis E virus genotype 4 outbreak, Italy, 2011. Emerg Infect Dis. 2013;19:110-4.
56. Anty R, Ollier L, Peron JM, Nicand E, Cannavo I, Bongain A, et al. First case report of an acute genotype 3 hepatitis E infected pregnant woman living in South-Eastern France. J Clin Virol. 2012;54:76-8.
57. Dalton HR, Bendall RP, Rashid M, Ellis V, Ali R, Ramnarace R, et al. Host risk factors and autochthonous hepatitis E infection. Eur J Gastroenterol Hepatol. 2011;23:1200-5.
58. Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429-35. (Pubitemid 350045603)
59. • Vine LJ, Shepherd K, Hunter JG, Madden R, Thornton C, Ellis V, et al. Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment Pharmacol Ther. 2012;36:16-21. HEV is the commonest cause of acute viral hepatitis in Cornwall, U.K.
60. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIVinfection. N Engl J Med. 2009;361:1025-7.
61. • Versluis J, Pas SD, Agteresch HJ, de Man RA, Maaskant J, Schipper ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:1079-86. This is the first cohort study that describes chronic hepatitis E infections and reactivation of hematopoietic stem cell transplant recipients and the clinical presentation.
62. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2009;15:1225-8.
63. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811-7. (Pubitemid 351281642)
64. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14:547-53. (Pubitemid 351524412)
65. • Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481-9. This study provides the progression, outcomes, and factors associated with development of chronic HEVinfection in recipients of transplanted solid organs.
66. Koning L, Pas SD, de Man RA, Balk AH, de Knegt RJ, ten Kate FJ, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. J heart Lung Transplant Off Pub Int Soc Heart Transplant. 2013;32:78-85.
67. Riezebos-Brilman A, Verschuuren EA, van Son WJ, van Imhoff GW, Brugemann J, Blokzijl H, et al. The clinical course of hepatitis E virus infection in patients of a tertiary Dutch hospital over a 5-year period. J Clin Virol 2013.
68. Colson P, Kaba M, Moreau J, Brouqui P. Hepatitis E in an HIV-infected patient. J Clin Virol. 2009;45:269-71.
69. Abravanel F, Mansuy JM, Huynh A, Kamar N, Alric L, Peron JM, et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol. 2012;54:152-5.
70. Koenecke C, Pischke S, Heim A, Raggub L, Bremer B, Raupach R, et al. Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country? Transpl Infect Dis. 2012;14:103-6.
71. le Coutre P, Meisel H, Hofmann J, Rocken C, Vuong GL, Neuburger S, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58:699-702.
72. Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, Usama W, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20:784-90.
73. Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood. 2000;96:3290-3.
74. Wils EJ, van der Holt B, Broers AE, Posthumus-van Sluijs SJ, Gratama JW, Braakman E, et al. Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96:1846-54.
75. Wils EJ, Cornelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. Blood Rev. 2005;19:89-98. (Pubitemid 39643114)
76. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol. 1997;54:131-8. (Pubitemid 27079419)
77. Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med. 2008;358:859-60. (Pubitemid 351281667)
78. •• Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis. 2011;17:173-9. In a large Anglo-French cohort of acute and chronic hepatitis E patients, neurological complications were seen in 5%. In these cases, the LFTs were only mildly abnormal, and the neurological symptoms and signs completely dominated the clinical picture.
79. Comont T, Bonnet D, Sigur N, Gerdelat A, Legrand-Abravanel F, Kamar N, et al. [Acute hepatitis E infection associated with Guillain-Barre syndrome in an immunocompetent patient.]. La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne 2013.
80. •• van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Thio-Gillen AP, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. In press, Neurology. A case control study of 201 patients with Guillain-Barré syndrome from the Netherlands. Of patients with Guillain-Barré syndrome, 5% were shown to have hepatitis E at the onset of their neurological illness. The LFTs were mildly abnormal, neurological symptoms and signs dominated the clinical picture, and HEV-associated Guillain-Barré syndrome was clinically indistinguishable from cases not associated with HEV.
81. •• van Eijk JJ, Madden RG, van der Eijk AA, Hunter JG, Reimerink JHJ, Bendall RP, et al. Neuralgic amyotrophy and hepatitis E virus infection. submitted. An Anglo-Dutch cohort study of 47 patients with neuralgic amyotrophy. Of patients with neuralgic amyotrophy, 10% were shown to have hepatitis E at the onset of their neurological illness. The LFTs were mildly abnormal; neurological symptoms and signs dominated the clinical picture.
82. Tamura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, Takahashi K, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res. 2007;37:113-20. (Pubitemid 46403826)
83. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, et al. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transf Med (Oxf Engl). 2006;16:79-83. (Pubitemid 43935063)
84. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368-75.
85. Matsubayashi K, Nagaoka Y, Sakata H, Sato S, Fukai K, Kato T, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:934-40. (Pubitemid 38738426)
86. Colson P, Coze C, Gallian P, Henry M, De Micco P, Tamalet C. Transfusion-associated hepatitis E, France. Emerg Infect Dis. 2007;13:648-9.
87. Peron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J hepatol. 2011;54:1323-4. This is the first structural and funtional study on hepatitis E virus using crystallography, giving insight on virus-host interactions.
88. Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33:722-6.
89. Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010;16:474-7.
90. Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30-3.
91. Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. Semin Liver Dis. 2013;33:62-70.
92. Dalton HR, Keane FE, Bendall R, Mathew J, Ijaz S. Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med. 2011;155:479-80.
93. Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssiere L, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation. 2010;89:353-60.
94. Selves J, Kamar N, Mansuy JM, Peron JM. Hepatitis E virus: a new entity. Ann Pathol. 2010;30:432-8.
95. • Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology. 2010;139:1612-8. This is the first study to describe ribavirine as an option for hepatitis E virus infection treatment.
96. Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A. 1997;94:9860-5. (Pubitemid 27408155)
97. Mansuy JM, Legrand-Abravanel F, Calot JP, Peron JM, Alric L, Agudo S, et al. High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol. 2008;80:289-93.
98. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012;50:2708-13.
99. • Baylis SA, Gartner T, Nick S, Ovemyr J, Blumel J. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang. 2012;103:89-90. This is a very nice overview of the incidence of hepatitis E virus in blood donors in industrialized countries.
100. Zaaijer HL, Kok M, Lelie PN, Timmerman RJ, Chau K, van der Pal HJ. Hepatitis E in The Netherlands: imported and endemic. Lancet. 1993;341:826.
101. Ijaz S, Szypulska R, Tettmar KI, Kitchen A, Tedder RS. Detection of hepatitis E virus RNA in plasma mini-pools from blood donors in England. Vox Sang. 2012;102:272.
102. Bernal W, Smith HM, Williams R. A community prevalence study of antibodies to hepatitis A and E in inner-city London. J Med Virol. 1996;49:230-4. (Pubitemid 26291389)
103. Olsen B, Axelsson-Olsson D, Thelin A, Weiland O. Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls. Scand J Infect Dis. 2006;38:55-8. (Pubitemid 43123844)
104. Cleland A, Smith L, Crossan C, Blatchford O, Dalton HR, Scobie L, et al. Hepatitis E virus in Scottish blood donors. Vox Sang 2013.
105. Xu C, Wang RY, Schechterly CA, Ge S, Shih JW, Xia NS, et al. An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion 2013.
106. Said B, Ijaz S, Kafatos G, Booth L, Thomas HL, Walsh A, et al. Hepatitis E outbreak on cruise ship. Emerg Infect Dis. 2009;15:1738-44.
107. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665-72.e9.